Citryll Doses First Patient in Phase IIa Hidradenitis Suppurativa Trial for CIT-013
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Globenewswire
- Trial Initiation: Citryll has commenced its Phase IIa clinical trial for CIT-013 targeting moderate to severe hidradenitis suppurativa in Oss, Netherlands, with the first patient dosed, marking a significant advancement in treating immune-mediated inflammatory diseases.
- Patient Cohort Size: The trial will enroll 96 participants over a 12-week period to assess the efficacy, safety, and tolerability of CIT-013, addressing a critical gap in treatment options currently available for this condition.
- Advisory Board Formation: Citryll has established a Clinical Advisory Board comprising global dermatology experts to provide strategic guidance throughout the trial, enhancing the company’s credibility and expertise in the field.
- Innovative Treatment Mechanism: As the first monoclonal antibody targeting extracellular traps, CIT-013 features a unique dual mechanism of action that may offer more effective treatment options for hidradenitis suppurativa and other inflammatory diseases, positioning the company for long-term growth in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CITR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CITR
About CITR
General Enterprise Ventures, Inc. is a flame retardant and flame suppression company for the residential home industry. The Company's products include MFB31- CitroTech, which is utilized in wildfire defense, and MFB34-CitroTech, which is used to treat lumber to inhibit fire and mold. It is developing a coating to treat lumber during manufacture prior to distribution. The Company holds various intellectual property in the form of patents and trademarks in the fields of fire suppression, mapping and tracking of fire-retardant dispersion and fire inhibition chemistry and technology. Its products are used in the residential home industry, including individual homeowners, developers and other third parties. The Company installs systems to deploy its product remotely to provide a buffer zone around properties to prevent combustion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ServisFirst Bancshares Surges 13.1%, Leading Banking Sector Gains
- Strong Banking Sector Performance: Banking and savings stocks collectively rose by approximately 3.1%, indicating a renewed market confidence in the financial sector, which may attract more investor interest in this area.
- ServisFirst Bancshares Leads Gains: ServisFirst Bancshares saw its stock price increase by about 13.1%, making it one of the best performers of the day, reflecting strong market performance and positive investor sentiment.
- Dime Community Bancshares Follows Suit: Dime Community Bancshares' stock rose by approximately 12.4%, indicating significant market recognition for the company in the competitive banking industry, potentially driving its future growth prospects.
- Industry Trend Analysis: With the strong rebound in banking stocks, investors may reassess investment opportunities in the financial sector, especially against the backdrop of economic recovery, where banking profitability is expected to further improve.
Continue Reading
Citryll Doses First Patient in Phase IIa Hidradenitis Suppurativa Trial for CIT-013
- Trial Initiation: Citryll has commenced its Phase IIa clinical trial for CIT-013 targeting moderate to severe hidradenitis suppurativa in Oss, Netherlands, with the first patient dosed, marking a significant advancement in treating immune-mediated inflammatory diseases.
- Patient Cohort Size: The trial will enroll 96 participants over a 12-week period to assess the efficacy, safety, and tolerability of CIT-013, addressing a critical gap in treatment options currently available for this condition.
- Advisory Board Formation: Citryll has established a Clinical Advisory Board comprising global dermatology experts to provide strategic guidance throughout the trial, enhancing the company’s credibility and expertise in the field.
- Innovative Treatment Mechanism: As the first monoclonal antibody targeting extracellular traps, CIT-013 features a unique dual mechanism of action that may offer more effective treatment options for hidradenitis suppurativa and other inflammatory diseases, positioning the company for long-term growth in the biopharmaceutical sector.
Continue Reading